HBVaxPro

Hepatitis B surface antigen, recombinant · Merck Sharp & Dohme B.V.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for HBVaxPro, covering 2006-05-08 to 2025-11-07. Get the full timeline:

Most recent: EMA Authorised: HBVaxPro (hepatitis B, recombinant surface antigen) — Merck Sharp & Dohme B.V.